Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGB for Post Mastectomy Pain Syndrome
NCT04238377Unknown
- Sponsor
- National Cancer Institute
- Start
- Dec 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bupivacaine hydrochloride 0.75% injection in Post-mastectomy pain syndrome (PMPS), sponsored by National Cancer Institute. Primary endpoint: Incidence of Neuropathic Pain Syndromes at 6 months. Status: unknown.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
Post-mastectomy pain syndrome (PMPS)
Beyond the preview
Go deeper on NCT04238377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238377.